Surmodics, Inc. (NASDAQ:SRDX – Get Ranking) – Inventory analysts at Zacks Research lower their Q1 2024 earnings per share (EPS) estimates for shares of Surmodics in a analysis report issued to shoppers and buyers on Friday, December thirtieth. Zacks Research analyst D. Dey now forecasts that the corporate will earn $0.15 per share for the quarter, down from their earlier forecast of $0.18. The consensus estimate for Surmodics’ present full-year earnings is ($2.37) per share.

Surmodics (NASDAQ:SRDX – Get Ranking) final issued its earnings outcomes on Wednesday, November ninth. The corporate reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.12. Surmodics had a damaging return on fairness of 10.59% and a damaging internet margin of 27.29%. The corporate had income of $25.99 million through the quarter, in comparison with analysts’ expectations of $24.84 million.

Individually, StockNews.com assumed protection on Surmodics in a analysis report on Wednesday, October twelfth. They issued a “maintain” ranking for the corporate.

Surmodics Inventory Efficiency

NASDAQ SRDX opened at $34.12 on Monday. Surmodics has a fifty-two week low of $28.27 and a fifty-two week excessive of $50.85. The inventory has a 50 day easy shifting common of $34.45 and a two-hundred day easy shifting common of $34.14. The inventory has a market cap of $481.98 million, a P/E ratio of -17.41 and a beta of 0.97.

Insiders Place Their Bets

In different information, Director Jose H. Bedoya bought 4,366 shares of the agency’s inventory in a transaction on Monday, November twenty eighth. The inventory was bought at a median value of $34.89, for a complete worth of $152,329.74. Following the transaction, the director now immediately owns 24,192 shares within the firm, valued at roughly $844,058.88. The transaction was disclosed in a doc filed with the SEC, which is accessible by means of this hyperlink. In different information, Director Jose H. Bedoya bought 4,366 shares of the enterprise’s inventory in a transaction dated Monday, November twenty eighth. The inventory was bought at a median value of $34.89, for a complete worth of $152,329.74. Following the transaction, the director now immediately owns 24,192 shares within the firm, valued at $844,058.88. The sale was disclosed in a doc filed with the Securities & Alternate Fee, which is on the market by means of this hyperlink. Additionally, Director David Dantzker bought 2,773 shares of the enterprise’s inventory in a transaction dated Monday, November 14th. The shares have been bought at a median value of $33.00, for a complete worth of $91,509.00. Following the completion of the transaction, the director now owns 34,178 shares within the firm, valued at $1,127,874. The disclosure for this sale might be discovered right here. Within the final quarter, insiders bought 9,872 shares of firm inventory valued at $335,340. Company insiders personal 7.50% of the corporate’s inventory.

Institutional Inflows and Outflows

A number of massive buyers have not too long ago modified their holdings of the enterprise. Trigran Investments Inc. lifted its holdings in Surmodics by 3.4% through the second quarter. Trigran Investments Inc. now owns 2,208,548 shares of the corporate’s inventory value $82,224,000 after shopping for an extra 72,657 shares through the interval. Victory Capital Administration Inc. acquired a brand new place in shares of Surmodics through the third quarter value $782,000. Healthcare of Ontario Pension Plan Belief Fund acquired a brand new place in shares of Surmodics through the first quarter value $1,111,000. Vanguard Group Inc. elevated its place in shares of Surmodics by 2.6% through the first quarter. Vanguard Group Inc. now owns 930,838 shares of the corporate’s inventory value $42,196,000 after buying an extra 23,798 shares within the final quarter. Lastly, BlackRock Inc. elevated its place in shares of Surmodics by 0.8% through the first quarter. BlackRock Inc. now owns 2,284,644 shares of the corporate’s inventory value $103,565,000 after buying an extra 17,169 shares within the final quarter. Hedge funds and different institutional buyers personal 96.49% of the corporate’s inventory.

About Surmodics

(Get Ranking)

Surmodics, Inc, along with its subsidiaries, gives efficiency coating applied sciences for intravascular medical gadgets, and chemical and organic elements for in vitro diagnostic immunoassay checks and microarrays in the USA and internationally. It operates in two segments, Medical Machine and In Vitro Diagnostics (IVD).

Featured Tales

This immediate information alert was generated by narrative science know-how and monetary information from MarketBeat with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial staff previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.

Earlier than you think about Surmodics, you may wish to hear this.

MarketBeat retains observe of Wall Road’s top-rated and greatest performing analysis analysts and the shares they suggest to their shoppers each day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Surmodics wasn’t on the record.

Whereas Surmodics at the moment has a “Purchase” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.

View The 5 Shares Right here